|
1 2 3 4 5
читать далее ... ва, Россия, 1999: С. 5-8. 2. Hooton T.M., Stamm W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North. Am., 1997; 11 (З): 551-81. 3. Kahlmeter G. An International Survey of the Antimicrobial Susceptibility of pathogens from Uncomplicated Urinary Tract Infections: the ECO-SENS Project. J Antimicrob. Chemother., 2003; 51 (1): 69-76. 4. Karlowsky J.A., KellyL.J., ThornsberryC., JonesM.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Eschenchia coli from female outpatients in the United States. Anfimicrob. Agents Chemother., 2002; 46 (8): 2540-5. 5. Raz R., Chazan В, Kennes Y., Colodner R., Rottensterich E., Dan M., Lavi /., Stamm W.. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis., 2002; 34(9): 1165-9. 6. Warren J.W., Abrutyn E., Hebel J.R.. Johnson J.R., Schaefter A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. • Infect. Dis., 1999:29(4); 745-58. 7. NCCLS Methods for Dilution Anfimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standart, 6th ed, 2002:20: 1-45. 8. Comite de I'antibiogramme de la societe francaise de micmbiologie (CA-SFM): report 2003. Zone sizes and MIC breakpoints for non-fastidious organisms (http://www.sfm.asso.fr/). 9. Mazzulli Т., SarabiaA., Marshall W e.a. Susceptibility of Communiti Urinary Uract Isolates to Commonly Used Oral Antimicrobial Agents. 42nd ICAAC Abstract, San Diego, California, September 27-30, 2002. Abstract C2-318. 10. Козлов С.Н., Рачина С.А., Домникова Н.П., Карпов ОМ., Кузин 8.6., Лещенко И.В. и др. Фармакоэпидемиологический анализ печения внебольничной пневмонии в амбулаторных условиях. Клиническая микробиология и антимикробная химиотерапия, 2000; №3: 74-81. 11. Андреева И.В., Рачина С.А., Петроченкова НА., Галкин Д.В., Горенкова Е.В. и др. Самостоятельное применение антимикробных лекарств населением: результаты многоцентрового исследования. Клиническая фармакология и терапия, 2002: N''3:15-26. 12. Bergogne-Berezin E., BerthelotG., Muller-Serieys С. Present status of nitroxoline. Pathol Biol, 1987: 35(5 Pt 2); 873-8. 13. JickS.S., JickH., Walker A.M., Hunter J.R. Hospitalizations for pulmonary reactions following nitrofurantoin use. Chest, 1989; 96 (3); 512-5. 14. Westphal J.F., Vetter D., Brogard J.M. Hepatic side-effects of antibiotics. J Antimicrob. Chemother., 1994; 33 (З): 387-401. 15. Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J Antimicrob. Agents, 2001:18(3): 211-5. 16. Holmes В., Brogden R.H., Richards D.M. Norfloxacin. A review of its antibacterial activity, pharИсточник: Рафальский В.В. и др. Русский медицинский журнал. 2006. Т.14. №4. С.341-344
|
